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Abstract
Background:  Inconsistent findings have been reported on the occurrence and relevance of
creatine kinase (CK) isoenzymes in mammalian liver cells. Part of this confusion might be due to
induction of CK expression during metabolic and energetic stress.
Methods: The specific activities and isoenzyme patterns of CK and adenylate kinase (AdK) were
analysed in pathological liver tissue of patients undergoing orthotopic liver transplantation.
Results: The brain-type, cytosolic BB-CK isoenzyme was detected in all liver specimens analysed.
Conversely, CK activity was strongly increased and a mitochondrial CK (Mi-CK) isoenzyme was
detected only in tissue samples of two primary hepatocellular carcinomas (HCCs).
Conclusion: The findings do not support significant expression of CK in normal liver and most
liver pathologies. Instead, many of the previous misconceptions in this field can be explained by
interference from AdK isoenzymes. Moreover, the data suggest a possible interplay between p53
mutations, HCC, CK expression, and the growth-inhibitory effects of cyclocreatine in HCC. These
results, if confirmed, could provide important hints at improved therapies and cures for HCC.
Background
Creatine kinase (CK) isoenzymes catalyse the reversible
transfer of the phosphate group of phosphocreatine (PCr)
to ADP, to yield ATP and creatine (Cr). The CK/PCr/Cr
system is present primarily in tissues with high and fluctu-
ating energy demands such as brain, heart and skeletal
muscle, and serves as a temporal and spatial "energy
buffer" that helps to maintain a high intracellular phos-
phorylation potential in situations of increased metabolic
demand (for reviews, see [1,2]).
In mammals, Cr can be taken up by the intestine from the
food, or can be synthesized de novo. The liver is the main
site of Cr production in the body (see [2]). After its synthe-
sis, Cr is transported through the blood and is taken up by
Cr-containing tissues via a specific Cr transporter.
Whereas the importance of the liver in Cr biosynthesis is
undisputed, some confusion still exists on the CK activity
and PCr content in this organ. The majority of findings
suggest no or minute levels of CK and PCr in liver tissue
and, in particular, in hepatocytes (e.g., [3-6]). Other stud-
ies that used more sensitive experimental approaches pro-
vided evidence for low levels of PCr and CK, specifically
localized in sinusoidal endothelial cells ([7-9]; see also
[10]). Finally, in a few cases, more extreme findings were
made: unusually high levels of CK activity were measured
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in liver tissue by Shatton et al. [11], Goullé et al. [12], and
Wali & Makinde [13].
The majority of studies indicated that the low levels of CK
activity in liver are due solely to the brain-type cytosolic
CK (BB-CK) isoenzyme. On the other hand, besides BB-
CK which was suggested to be present in endothelial and
Kupffer cells, Vaubourdolle et al. [14] also provided evi-
dence for the presence of the muscle-type cytosolic (MM-
CK) isoenzyme in Ito cells, and for mitochondrial CK (Mi-
CK) in hepatocytes. Similarly, Kanemitsu et al. [15] puri-
fied Mi-CK from normal human liver, which would imply
significant amounts of this isoenzyme in liver tissue.
Finally, increases in serum CK activity were frequently
observed in cases of severe liver disease, with the most
obvious source of CK being the pathological liver tissue
itself [16-18].
In a number of studies reporting significant levels of CK
activity in liver, interference by adenylate kinase (AdK)
isoenzymes in the CK activity assays [19-21] is very likely
(e.g., [13]), or can at least not be excluded, thus question-
ing the validity of these studies. Another possible cause for
inconsistent findings might be compensatory up-regula-
tion of CK expression in pathological liver tissue. Two
lines of evidence that favour this hypothesis are: (i) par-
tially hepatectomized rat liver was reported to show an
increase in BB-CK activity (see [22]); and (ii) overexpres-
sion of CK isoenzymes in the liver of transgenic mice was
shown to stabilize energy metabolism under low-oxygen
stress and after a metabolic challenge [23,24], to acceler-
ate regeneration of liver mass following major hepatec-
tomy [10,25], and to increase endotoxin tolerance [5,26].
Because of these conflicting data, the goal of the present
study was to analyse in detail the CK and AdK activities in




The present project was approved by the ethics commis-
sion of the University of Innsbruck. In total, 25 liver sam-
ples were analysed. Twenty-three samples were obtained
from 18 explanted organs of liver transplant recipients,
one sample was obtained at autopsy (no. 1), and the last
sample was from a normal rat liver. According to patho-
morphological criteria, the 25 samples can be divided into
5 groups: (1) Nine samples of cirrhotic liver tissue (nos. 5,
7, 11, 13, 17–19, 23, 24: 4 due to hepatitis B or C virus
infection, 3 due to primary or secondary biliary cirrhosis,
1 due to chronic alcohol abuse, and 1 due to vena hepat-
ica occlusion); (2) six samples of neoplastic tissue (nos. 4,
9, 14, 15, 20, 21: 3 cholangiocellular carcinomas, 2 pri-
mary hepatocellular carcinomas, and 1 liver metastasis of
a malignant melanoma); (3) three samples of necrotizing
liver tissue due to acute or subacute organ rejection (nos.
2, 6, 22); (4) five samples of macroscopically normal liver
parenchymal tissue (nos. 3, 8, 10, 16, 25) surrounding
focal liver pathologies (i.e., 2 primary HCCs [samples 4
and 9]; metastasis of malignant melanoma [sample 15];
vena hepatica occlusion [sample 24]); (5) two samples
originating from a normal rat liver (no. 12) and from a
patient with steatosis hepatis (no. 1).
Preparation of homogenate, cytosolic and mitochondrial 
fractions of human and rat liver
All steps were performed on ice or at 4°C. Approximately
5 g of liver tissue was homogenized in 45 ml buffer A (250
mM sucrose, 5 mM HEPES, 0.5 mM EGTA, pH 7.4). The
homogenate was subjected to centrifugation for 5 min at
800 g. The pellet was discarded, and the supernatant cen-
trifuged for 4 min at 5,100 g (centrifugation C2). The
supernatant of C2 was further clarified by centrifugation
for 12 min at 12,300 g, thus yielding the cytosolic frac-
tion. The pellet of C2 was resuspended in 10 ml buffer A,
followed by centrifugation for 2 min at 12,300 g (C3).
After resuspension of the C3 pellet in 10 ml buffer A and
centrifugation for a further 10 min at 12,300 g, the sedi-
ment was resuspended in 4 ml buffer A, thus yielding the
mitochondrial fraction. One-ml aliquots of the different
fractions were immediately frozen in liquid nitrogen and
stored at -80°C until analysis.
Measurements of CK and AdK activity
For CK and AdK activity measurements, the following
assay medium was used: 110 mM imidazole, pH 6.7, 20.5
mM glucose, 11 mM Mg-acetate, 2.05 mM EDTA·Na2, 2.1
mM ADP, 2.1 mM NADP, 21 mM N-acetylcysteine, 9 U/
ml of hexokinase, and 5.8 U/ml of glucose-6-phosphate
dehydrogenase (both from Sigma). Enzymatic activity
was measured at 25°C as an increase in NADPH absorb-
ance at 340 nm. For AdK, three separate measurements
were made for each sample in the same assay medium. For
CK measurements, 5.1 mM AMP was added to the assay
medium to inhibit AdK activity. For each sample, three
measurements with 10.3 mM PCr and three measure-
ments without PCr (blank measuring residual AdK activ-
ity after inhibition with AMP) were made, and the CK
activity was calculated as the difference of the respective
means. All values in this paper represent specific activities
per mg of homogenate, cytosolic or mitochondrial pro-
tein. Protein amounts were measured according to the
method of Bradford [27] with bovine serum albumin as
standard.
Cellulose polyacetate electrophoresis (CPE)
CPE was performed at room temperature for 90 min at a
constant voltage of 150 V, but otherwise as described pre-
viously [28]. CK and AdK isoenzyme bands wereBMC Gastroenterology 2005, 5:9 http://www.biomedcentral.com/1471-230X/5/9
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visualized at 37°C with an overlay gel technique in a reac-
tion protocol similar to the one described above for the
measurement of enzymatic activity. NADPH was reacted
with nitrobluetetrazolium in the presence of phenazine
methosulfate to yield formazan. For visualization of CK
bands, AMP was added to the overlay gel to inhibit AdK
activity. Since AMP alone may not be sufficient to inhibit
all AdK activity [21], two identical cellulose polyacetate
strips were run; one was developed with PCr in the overlay
gel, whereas for the other, PCr was omitted from the over-
lay gel (blank).
Results
CK and AdK activities were measured in total homogenate
(Fig. 1), cytosolic and mitochondrial fractions (data not
shown) obtained by differential centrifugation from 25
normal and pathological liver samples. Highest CK activ-
ities were observed in the two primary HCCs analysed
(liver samples no. 4 and 9), with specific CK activities in
the homogenate of 0.36 and 0.21 U·(mg protein)-1,
respectively. In most other liver samples, the specific CK
activities in the homogenate were below 0.05 U·(mg pro-
tein)-1. Whereas enzymatic activity measurements
revealed low, but consistent CK activity in many of the
cytosolic fractions, no CK activity was detected in the
mitochondrial fractions, except for HCC sample no. 9
with a specific CK activity of approx. 0.1 U·(mg protein)-
1 (due to limited sample size, subcellular fractionation
was not feasible for HCC sample no. 4). These findings
were corroborated qualitatively by isoenzyme electro-
phoresis on cellulose polyacetate strips. Visualization of
the different CK isoenzymes by an overlay gel technique
revealed that the brain-type cytosolic BB-CK isoenzyme
was present in all liver samples. Conversely, bands for the
dimeric and octameric forms of Mi-CK were only
observed in the two primary HCC samples (nos. 4 and 9;
Fig. 2).
The CK/AdK activity ratio in the homogenate was 1.4 and
2.6 for the two primary HCCs (liver samples no. 4 and 9,
respectively), 0.5 for liver sample no. 5 (secondary biliary
cirrhosis), and < 0.2 for all other liver samples. Similar
findings were made for the cytosolic and mitochondrial
fractions, with CK/AdK activity ratios of < 0.3 for the
cytosolic fraction and < 0.05 for the mitochondrial frac-
tion. For HCC sample no. 9, however, these ratios were
significantly higher: 4.8 (cytosolic fraction) and 0.33
(mitochondrial fraction).
Discussion
CK is an enzyme still widely analysed in clinical diagnos-
tics. Although a wealth of CK measurements have been
reported in the scientific literature, there still exist incon-
sistency and incomplete knowledge on such an appar-
ently simple question as the CK (isoenzyme) content of
mammalian liver in both health and disease. In the
present study, we detected the presence of BB-CK in all
liver samples analysed by using CK activity measurements
and cellulose polyacetate electrophoresis. However, in the
normal and most pathological liver samples that we ana-
lysed, the specific CK activity was very low (< 0.05 U·[mg
protein]-1), levels which are comparable with or lower
than data reported for rat and human liver [29,30], but
much lower than the specific CK activities in skeletal mus-
cle, heart and brain (2–37 U·[mg protein]-1; [29,31-33]).
We additionally observed that (i) the specific AdK activi-
ties in these samples were consistently higher than the
specific CK activities (on average, > 10-fold), (ii) both
activity measurements and cellulose polyacetate electro-
phoresis revealed similar specific AdK activities in the
cytosolic and mitochondrial fractions (although from dif-
ferent AdK isoenzymes; data not shown), and (iii) mito-
chondrial respiration, in the presence of ATP, could be
fully stimulated by AMP, but not by creatine (data not
shown). This last observation favours the interpretation
that in normal hepatocytes, CK isoenzymes are not
expressed, and that the AdK isoenzyme system plays a
function in high-energy phosphate buffering and trans-
port, which is similar to the role of CK in brain, skeletal
muscle and heart. Although histochemical data are miss-
ing, the results obtained here are most consistent with a
localization of small amounts of BB-CK in sinusoidal
endothelial cells [14].
Interestingly, we observed a strong induction of both BB-
CK and Mi-CK expression in two samples of primary
HCC. Despite CK/AdK activity ratios in vitro of 1.4–2.6,
the specific CK activities were still relatively low (0.21–
0.36 U·[mg protein]-1). Therefore, in the absence of his-
tochemical data, it cannot be concluded with certainty
whether the increased levels of CK are due to increased
vascularization of the tumour (possibly associated with a
higher proportion of CK-containing endothelial cells), or
to induction of CK expression in the malignant cells.
Induction of CK expression has been observed previously
in many types of tumours (see [2]) and may reflect an
adaptation of the tumour tissue to the increased energetic
demands. Evidence for induction of CK in liver tumours
mostly comes from hepatoma cells grown in tissue culture
[34,35] or, indirectly, from increased amounts of circulat-
ing BB-CK and Mi-CK in the blood of patients with liver
tumours [36]. On the other hand, analysis of the tumour
tissue itself, both by classical biochemical methods and by
microarray technology, provided inconsistent results.
Some authors reported induction of CK expression in liver
tumours ([37-39]; and, in part, [40]; M. Sakamoto and S.
H. Yim, personal communication), others repression
[41], and still others observed no statistically significant
differences between normal and malignant liver tissueBMC Gastroenterology 2005, 5:9 http://www.biomedcentral.com/1471-230X/5/9
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[11,30]. This may be a reflection of the diverse clinico-
pathological and biological phenotypes of HCC, with dif-
ferent underlying molecular defects.
A key player in the picture might be the p53 tumour sup-
pressor gene. Mutations in p53 are quite prevalent in
HCC, especially in tumours with low cellular
CK and AdK activities in pathological and normal liver tissue Figure 1
CK and AdK activities in pathological and normal liver tissue. Specific CK (A) and AdK activities (B) in total homoge-
nate fractions were determined as described under "Methods". The liver samples were classified into five groups: group 1 – cir-
rhotic liver tissue (nos. 5, 7, 11, 13, 17–19, 23, 24); group 2 – neoplastic tissues (nos. 4, 9, 14, 15, 20, 21; 2 primary 
hepatocellular carcinomas [nos. 4 and 9]; 3 cholangiocellular carcinomas [nos. 14, 20 and 21]; 1 liver metastasis of a malignant 
melanoma [no. 15]); group 3 – samples of necrotizing liver tissue due to acute or subacute organ rejection (nos. 2, 6, 22); 
group 4 – samples of macroscopically normal liver parenchymal tissue (nos. 3, 8, 10, 16, 25) surrounding focal liver pathologies 
(2 primary HCCs [nos. 4 and 9]; metastasis of malignant melanoma [no. 15]; vena hepatica occlusion [no. 24]); group 5 – sam-
ples originating from a normal rat liver (no. 12) and from a patient with steatosis hepatis (no. 1). No AdK activity measure-
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differentiation [42,43]. On the other hand, p53 was
shown to control BB-CK expression: transrepression as
observed for wild-type p53 is prevented by different muta-
tions in the p53 gene [44]. Therefore, it is tempting to
speculate that induction of BB-CK in HCCs is caused
directly or indirectly by mutations in p53.
Expression of CK in HCC may have therapeutic implica-
tions, which is all the more important given (i) the limited
responsiveness of HCC to currently available therapeutic
approaches and, thus, (ii) the poor prognosis associated
with this disease. Cr analogues (cyclocreatine and β -gua-
nidinopropionic acid) and also Cr itself were previously
shown to have antitumour activity, both in cell culture
and in in vivo models ([45,46]; see also [2]). The
responsiveness of tumour cells to growth inhibition by
cyclocreatine seems to be correlated with their specific CK
activity; cell lines with a specific CK activity of > 0.10
U·(mg protein)-1 were generally sensitive to the drug. As
for the liver, β -guanidinopropionic acid and creatine
slowed the growth of AS30-D ascites tumour cells in cul-
ture (chemically induced rat hepatoma; [34]). Similarly,
cyclocreatine revealed antitumour effects in a rat model of
chemically induced hepatocarcinogenesis [47].
Conclusion
The present findings shed light on some old enigmas and
open up fascinating avenues for future research. Our find-
ings do not support significant expression of CK in nor-
mal liver and most liver pathologies, but rather indicate
that many of the previous misconceptions in this field can
be explained by interference from AdK isoenzymes. On
the other hand, given the need for improved understand-
ing of the molecular pathogenesis of HCC, and for
improved therapies and cures, the induction of CK expres-
sion in HCC described here calls for a more in-depth anal-
ysis of the interplay between p53 mutations, HCC, CK
expression, and the growth-inhibitory effects of cyclocrea-
tine in HCC.
List of abbreviations
AdK, adenylate kinase; BB-CK, brain-type cytosolic CK
isoenzyme; CK, creatine kinase; Cr, creatine; HCC, hepa-
tocellular carcinoma; Mi-CK, mitochondrial CK; MM-CK,
CK isoenzymes in HCC Figure 2
CK isoenzymes in HCC. Subcellular fractions of HCC liver samples no. 4 (A, B) and 9 (C, D) were analysed by cellulose 
polyacetate electrophoresis as described under "Methods". H = total homogenate; C = cytosolic fraction; M = mitochondrial 
fraction; Ct = control containing BB-CK and Mi-CK; Mi-CKd = dimeric Mi-CK; Mi-CKo = octameric Mi-CK; O = place of sam-
ple application. The cellulose polyacetate strips were exposed to an overlay gel containing PCr (A, C = CK activity staining), or 
lacking PCr (B, D = corresponding negative controls). Whereas Mi-CKd and Mi-CKo were well separated in (A), they were 
less so in (C).
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muscle-type cytosolic CK isoenzyme; PCr,
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